Is Chelation Therapy a Potential Treatment for Parkinson's Disease?

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2021 Apr 3

PMID 33805195

Citations 11

Authors

Roberta J Ward

David T Dexter

Antonio Martin-Bastida

Robert R Crichton

Affiliations

Soon will be listed here.

Abstract

Iron loading in some brain regions occurs in Parkinson's Disease (PD), and it has been considered that its removal by iron chelators could be an appropriate therapeutic approach. Since neuroinflammation with microgliosis is also a common feature of PD, it is possible that iron is sequestered within cells as a result of the "anaemia of chronic disease" and remains unavailable to the chelator. In this review, the extent of neuroinflammation in PD is discussed together with the role played by glia cells, specifically microglia and astrocytes, in controlling iron metabolism during inflammation, together with the results of MRI studies. The current use of chelators in clinical medicine is presented together with a discussion of two clinical trials of PD patients where an iron chelator was administered and showed encouraging results. It is proposed that the use of anti-inflammatory drugs combined with an iron chelator might be a better approach to increase chelator efficacy.

Citing Articles

Amphetamine-like Deferiprone and Clioquinol Derivatives as Iron Chelating Agents.

El Safadi M, Wilson K, Strudwicke I, OMara M, Bhadbhade M, Rawling T Molecules. 2024; 29(17).

PMID: 39275060 PMC: 11397356. DOI: 10.3390/molecules29174213.

The Irony of Iron: The Element with Diverse Influence on Neurodegenerative Diseases.

Lee S, Kovacs G Int J Mol Sci. 2024; 25(8).

PMID: 38673855 PMC: 11049980. DOI: 10.3390/ijms25084269.

Efficacy of the iron-chelating agent, deferiprone, in patients with Parkinson's disease: A systematic review and meta-analysis.

Negida A, Hassan N, Aboeldahab H, Zain Y, Negida Y, Cadri S CNS Neurosci Ther. 2024; 30(2):e14607.

PMID: 38334258 PMC: 10853946. DOI: 10.1111/cns.14607.

Dyshomeostasis of Iron and Its Transporter Proteins in Cypermethrin-Induced Parkinson's Disease.

Sachan N, Tiwari N, Patel D, Katiyar D, Srikrishna S, Singh M Mol Neurobiol. 2023; 60(10):5838-5852.

PMID: 37351784 DOI: 10.1007/s12035-023-03436-2.

Gut Dysbiosis: A Target for Protective Interventions against Parkinson's Disease.

Lima I, Pego A, Martins A, Prada A, Barros J, Martins G Microorganisms. 2023; 11(4).

PMID: 37110302 PMC: 10146107. DOI: 10.3390/microorganisms11040880.

References

Olivieri N, Nathan D, MacMillan J, Wayne A, Liu P, McGee A . Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med. 1994; 331(9):574-8. DOI: 10.1056/NEJM199409013310903. View

Oliveira Barbosa J, Santos A, Tumas V, Liu M, Zheng W, Haacke E . Quantifying brain iron deposition in patients with Parkinson's disease using quantitative susceptibility mapping, R2 and R2. Magn Reson Imaging. 2015; 33(5):559-65. DOI: 10.1016/j.mri.2015.02.021. View

Martin-Bastida A, Pietracupa S, Piccini P . Neuromelanin in parkinsonian disorders: an update. Int J Neurosci. 2017; 127(12):1116-1123. DOI: 10.1080/00207454.2017.1325883. View

Cukierman D, Lazaro D, Sacco P, Ferreira P, Diniz R, Fernandez C . X1INH, an improved next-generation affinity-optimized hydrazonic ligand, attenuates abnormal copper(I)/copper(II)-α-Syn interactions and affects protein aggregation in a cellular model of synucleinopathy. Dalton Trans. 2020; 49(45):16252-16267. DOI: 10.1039/d0dt01138j. View

Nathan D . Thalassemia: a look to the future. Ann N Y Acad Sci. 2016; 1368(1):11-5. DOI: 10.1111/nyas.13002. View

Schenck J . Magnetic resonance imaging of brain iron. J Neurol Sci. 2003; 207(1-2):99-102. DOI: 10.1016/s0022-510x(02)00431-8. View

Bartels A, Willemsen A, Doorduin J, de Vries E, Dierckx R, Leenders K . [11C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson's disease?. Parkinsonism Relat Disord. 2009; 16(1):57-9. DOI: 10.1016/j.parkreldis.2009.05.005. View

Zhang W, Phillips K, Wielgus A, Liu J, Albertini A, Zucca F . Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson's disease. Neurotox Res. 2009; 19(1):63-72. PMC: 3603276. DOI: 10.1007/s12640-009-9140-z. View

Ben-Shachar D, Riederer P, Youdim M . Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease. J Neurochem. 1991; 57(5):1609-14. DOI: 10.1111/j.1471-4159.1991.tb06358.x. View

10.

Zhang H, Bai L, He J, Zhong L, Duan X, Ouyang L . Recent advances in discovery and development of natural products as source for anti-Parkinson's disease lead compounds. Eur J Med Chem. 2017; 141:257-272. DOI: 10.1016/j.ejmech.2017.09.068. View

11.

Lewis M, Du G, Kidacki M, Patel N, Shaffer M, Mailman R . Higher iron in the red nucleus marks Parkinson's dyskinesia. Neurobiol Aging. 2012; 34(5):1497-503. PMC: 3570638. DOI: 10.1016/j.neurobiolaging.2012.10.025. View

12.

Rathore K, Redensek A, David S . Iron homeostasis in astrocytes and microglia is differentially regulated by TNF-α and TGF-β1. Glia. 2012; 60(5):738-50. DOI: 10.1002/glia.22303. View

13.

Hadzhieva M, Kirches E, Mawrin C . Review: iron metabolism and the role of iron in neurodegenerative disorders. Neuropathol Appl Neurobiol. 2013; 40(3):240-57. DOI: 10.1111/nan.12096. View

14.

Nathan D . Thalassemia: the continued challenge. Ann N Y Acad Sci. 2005; 1054:1-10. DOI: 10.1196/annals.1345.001. View

15.

Fernandez B, Ferrer I, Gil F, Hilfiker S . Biomonitorization of iron accumulation in the substantia nigra from Lewy body disease patients. Toxicol Rep. 2017; 4:188-193. PMC: 5436624. DOI: 10.1016/j.toxrep.2017.03.005. View

16.

Bergeron R, Wiegand J, McManis J, Bharti N . Desferrithiocin: a search for clinically effective iron chelators. J Med Chem. 2014; 57(22):9259-91. PMC: 4255733. DOI: 10.1021/jm500828f. View

17.

Finkelstein D, Billings J, Adlard P, Ayton S, Sedjahtera A, Masters C . The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's disease. Acta Neuropathol Commun. 2017; 5(1):53. PMC: 5490188. DOI: 10.1186/s40478-017-0456-2. View

18.

Baker E, Wong A, Peter H, Jacobs A . Desferrithiocin is an effective iron chelator in vivo and in vitro but ferrithiocin is toxic. Br J Haematol. 1992; 81(3):424-31. DOI: 10.1111/j.1365-2141.1992.tb08251.x. View

19.

Dringen R, Bishop G, Koeppe M, Dang T, Robinson S . The pivotal role of astrocytes in the metabolism of iron in the brain. Neurochem Res. 2007; 32(11):1884-90. DOI: 10.1007/s11064-007-9375-0. View

20.

Deistung A, Schweser F, Reichenbach J . Overview of quantitative susceptibility mapping. NMR Biomed. 2016; 30(4). DOI: 10.1002/nbm.3569. View